Suppliers / Sichuan Renan Pharmaceutical

Sichuan Renan Pharmaceutical

China Updated 9 July 2026

Sichuan Renan Pharmaceutical is an API manufacturer based in China. It holds 2 valid CEPs across a filed portfolio of 2 molecules. Its GMP standing is certified by MFDS (Korea), EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 21 March 2025 as NAI.

0
active US DMFs
2
valid CEPs
3
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 21 March 2025 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Yuechi, China Not on file
Guangan, China Not on file
China, China 3016946731

What they file, and where

Molecule Regulators Docs
Gadobutrol EDQM 1
Nicergoline EDQM 1

Also appears on these molecule pages

Gadobutrol API

Filings and GMP by regulator

Regulator Filings GMP certificates
MFDS (Korea) None 4
EMA None 4
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Sichuan Renan Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 21 March 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates